GP2-funded training opportunity: Molecular Neurodegeneration and Therapeutic Approaches
We are pleased to announce that we will be funding up to ten places for participants from Lower and Middle Income Countries on the Wellcome Genome Campus course: Molecular Neurodegeneration and Therapeutic Approaches.
The virtual course will take place on January 25 – 29, 2021. It will provide an overview of the molecular basis of neurodegenerative disorders, including Parkinson’s disease. For more information about the course program, please visit the Wellcome Genome Campus Advanced Courses and Scientific Conferences website.
The course is aimed at individuals working in neurodegenerative research, neurogenetics or translational neuroscience, including clinical scientists, veterinary scientists, PhD students and post-doctoral researchers.
To be eligible for GP2 funding, you must live and work in a Lower and Middle Income Country (LMIC – see list of countries here).
To apply for a place on the course, submit your application through the Wellcome Genome Campus website. Places are awarded on merit by the conference organisers. You will be required to provide:
- A list of relevant publications
- An outline of current research and justification for attendance (250 word statement)
- Supervisor’s details: your supervisor will receive an e-mail requesting a supporting statement to complete your application.
Before applying through the Wellcome website, please inform the GP2 training team of your application by emailing [email protected]. To support your application, the GP2 training team can proofread the 250 word statement required for the application, however our support does not guarantee a place on the course.
In addition, to be considered for funding from GP2, once you have submitted your application please send a short email stating that you would like to be considered for GP2 funding to [email protected].
The application deadline is 23:59 UTC on November 23, 2020.